EyePoint Pharmaceuticals, Inc. — Director's Dealing 2019

Jun 17, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: EyePoint Pharmaceuticals, Inc. (EYPT)
CIK: 0001314102
Period of Report: 2019-06-14

Reporting Person: Lurker Nancy (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-06-14	Common Stock	M	45000.00	$0.00	Acquired	285200.00	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-06-14	Restricted Stock Units	$0.00	M	45000.00	Disposed		Common Stock (45000.00)	Direct

Footnotes

F1: Restricted stock units convert into common stock on a one-for-one basis.

F2: On June 14, 2018, the reporting person was granted 135,000 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date.